Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 15 | mg/kg | 6608000 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED40 | = | 10 | mg/kg | 6608000 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED30 | = | 11 | mg/kg | 2724294 |
NPT32 | Organism | Mus musculus | Mus musculus | ED50 | = | 7 | mg/kg | 2724294 |
NPT32 | Organism | Mus musculus | Mus musculus | ED50 | = | 0.2 | mg/kg | 2724294 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 1 | mg/kg | 2724294 |
NPT2 | Others | Unspecified | Ratio | = | 22 | 2724294 | ||
NPT1386 | Protein Family | Adrenergic receptor beta | Homo sapiens | Activity | = | -5.21 | 10.1016/S0960-894X(97)00046-2 | |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 0.94 | mg/kg | 10956225 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 66 | mg/kg | 10956225 |
NPT2 | Others | Unspecified | Kd | = | 26000 | nM | 10821711 | |
NPT32 | Organism | Mus musculus | Mus musculus | ED50 | = | 1.3 | mg/kg | 9544212 |
NPT4280 | Individual Protein | Prostaglandin-H2 D-isomerase | Mus musculus | IC50 | = | 13000 | nM | 1900533 |
NPT2 | Others | Unspecified | IC50 | > | 50 | ug | 9925732 | |
NPT1559 | Protein Family | Cyclooxygenase | Rattus norvegicus | ED50 | = | 0.94 | mg/kg | 9171873 |
NPT324 | Individual Protein | Cyclooxygenase-1 | Ovis aries | IC50 | = | 2700 | nM | 7562922 |
NPT31 | Individual Protein | Cyclooxygenase-2 | Homo sapiens | IC50 | = | 9700 | nM | 7562922 |
NPT1476 | Protein Family | Cyclooxygenase | Homo sapiens | Ratio | = | 0.3 | 7562922 | |
NPT521 | Cell Line | RBL-2H3 | Rattus norvegicus | Inhibition | > | 10000 | nM | 1635053 |
NPT183 | Individual Protein | Arachidonate 5-lipoxygenase | Rattus norvegicus | Inhibition | > | 20000 | nM | 1635053 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 53.7 | 2113951 | |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 0.99 | mg/kg | 15013005 |
NPT32 | Organism | Mus musculus | Mus musculus | ID50 | = | 140 | mg/kg | 6218302 |
NPT32 | Organism | Mus musculus | Mus musculus | ID50 | = | 411 | mg/kg | 6218302 |
NPT32 | Organism | Mus musculus | Mus musculus | LD50 | = | 1200 | mg/kg | 6218302 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 24.4 | mg/kg | 3086558 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 14 | % | 3086558 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 44 | % | 3086558 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 58 | % | 3086558 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 27 | % | 3086558 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 50 | % | 3086558 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 70 | % | 3086558 |
NPT1559 | Protein Family | Cyclooxygenase | Rattus norvegicus | IC50 | = | 60 | nM | 3086558 |
NPT183 | Individual Protein | Arachidonate 5-lipoxygenase | Rattus norvegicus | IC50 | = | 17000 | nM | 9057869 |
NPT30 | Individual Protein | Cyclooxygenase-1 | Homo sapiens | IC50 | = | 3200 | nM | 9057869 |
NPT31 | Individual Protein | Cyclooxygenase-2 | Homo sapiens | IC50 | = | 2500 | nM | 9057869 |
NPT324 | Individual Protein | Cyclooxygenase-1 | Ovis aries | IC50 | = | 21000 | nM | 8831759 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 14 | mg/kg | 12540240 |
NPT32 | Organism | Mus musculus | Mus musculus | ED50 | = | 1.3 | mg/kg | 9544211 |
NPT875 | Organism | Bos taurus | Bos taurus | IC50 | > | 30000 | nM | 7932530 |
NPT30 | Individual Protein | Cyclooxygenase-1 | Homo sapiens | IC50 | = | 350 | nM | 10.1016/0960-894X(96)00412-X |
NPT31 | Individual Protein | Cyclooxygenase-2 | Homo sapiens | IC50 | = | 24300 | nM | 10.1016/0960-894X(96)00412-X |
NPT32 | Organism | Mus musculus | Mus musculus | ED50 | = | 12 | mg/kg | 6972450 |
NPT32 | Organism | Mus musculus | Mus musculus | ED50 | = | 3 | mg/kg | 6972450 |
NPT32 | Organism | Mus musculus | Mus musculus | LD50 | > | 1000 | mg/kg | 6972450 |
NPT30 | Individual Protein | Cyclooxygenase-1 | Homo sapiens | IC50 | = | 11000 | nM | 10649977 |
NPT31 | Individual Protein | Cyclooxygenase-2 | Homo sapiens | IC50 | = | 18900 | nM | 10649977 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 5.2 | mg/kg | 10649977 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 6.1 | mg/kg | 10649977 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 0.8 | mg/kg | 10649977 |
NPT1476 | Protein Family | Cyclooxygenase | Homo sapiens | Ratio | = | 0.6 | 10649977 | |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 0.94 | mg/kg | 9135032 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 1.6 | mg/kg | 9135032 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 66 | % | 9135032 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Mortality | = | 50 | % | 15203134 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED30 | = | 11 | mg/kg | 3572970 |
NPT32 | Organism | Mus musculus | Mus musculus | ED50 | = | 7 | mg/kg | 3572970 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 0.2 | mg/kg | 3572970 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 1 | mg/kg | 3572970 |
NPT2 | Others | Unspecified | Therapeutic index | = | 22 | 3572970 | ||
NPT875 | Organism | Bos taurus | Bos taurus | IC50 | > | 30000 | nM | 10.1016/S0960-894X(01)80782-4 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 1.3 | mg/kg | 9719605 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 54 | % | 9719605 |
NPT324 | Individual Protein | Cyclooxygenase-1 | Ovis aries | Inhibition | < | 50 | % | 15369391 |
NPT3781 | Protein Family | Interleukin-8 receptors, CXCR1/CXCR2 | Homo sapiens | Inhibition | = | 35 | % | 15974585 |
NPT3782 | Protein Family | Prostaglandin G/H synthase (cyclooxygenase) | Mus musculus | Inhibition | > | 99 | % | 15974585 |
NPT3504 | Individual Protein | Aldo-keto-reductase family 1 member C3 | Homo sapiens | IC50 | = | 480 | nM | 16183274 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 51 | % | 16309906 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Activity | = | 28.7 | % | 16309906 |
NPT4149 | Protein Complex | Gamma-secretase | Homo sapiens | Inhibition | = | 3 | % | 16455248 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 68.3 | % | 17201408 |
NPT113 | Cell Line | RAW264.7 | Mus musculus | Activity | = | 5.70E-05 | ug/ml | 17383881 |
NPT113 | Cell Line | RAW264.7 | Mus musculus | Activity | = | 7.00E-05 | ug/ml | 17383881 |
NPT113 | Cell Line | RAW264.7 | Mus musculus | Activity | = | 0.000119 | ug/ml | 17383881 |
NPT113 | Cell Line | RAW264.7 | Mus musculus | Activity | = | 0.000106 | ug/ml | 17383881 |
NPT113 | Cell Line | RAW264.7 | Mus musculus | Activity | = | 7.50E-05 | ug/ml | 17383881 |
NPT113 | Cell Line | RAW264.7 | Mus musculus | Activity | = | 8.10E-05 | ug/ml | 17383881 |
NPT113 | Cell Line | RAW264.7 | Mus musculus | Ratio | = | 1 | 17383881 | |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 81.81 | % | 17576062 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 73.5 | % | 17576062 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Activity | = | 9.04 | nmol | 17576062 |
NPT30 | Individual Protein | Cyclooxygenase-1 | Homo sapiens | Inhibition | = | 39.3 | % | 18191402 |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 66.9 | % | 19272777 |
NPT32 | Organism | Mus musculus | Mus musculus | Activity | = | 49.2 | 10'5/cm'3 | 19272777 |
NPT31 | Individual Protein | Cyclooxygenase-2 | Homo sapiens | IC50 | = | 1010000 | nM | 9784154 |
NPT30 | Individual Protein | Cyclooxygenase-1 | Homo sapiens | IC50 | = | 11000 | nM | 9784154 |
NPT2 | Others | Unspecified | Ratio IC50 | = | 100 | 9784154 | ||
NPT1665 | Individual Protein | Cyclooxygenase-1 | Bos taurus | IC50 | = | 11000 | nM | 9461646 |
NPT325 | Individual Protein | Cyclooxygenase-2 | Ovis aries | IC50 | = | 1015000 | nM | 9461646 |
NPT2 | Others | Unspecified | Ratio IC50 | = | 96 | 9461646 | ||
NPT2 | Others | Unspecified | Inhibition | = | 9 | % | 18482840 | |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 50 | % | 18498150 |
NPT4281 | Cell Line | MC9 | Mus musculus | IC50 | = | 200 | nM | 18498150 |
NPT4281 | Cell Line | MC9 | Mus musculus | IC50 | = | 330 | nM | 18498150 |
NPT612 | Individual Protein | Canalicular multispecific organic anion transporter 1 | Homo sapiens | Activity | = | 92 | % | 18457386 |
NPT4064 | Individual Protein | Hormone-sensitive lipase | Rattus norvegicus | IC50 | = | 1200 | nM | 18808096 |
NPT4064 | Individual Protein | Hormone-sensitive lipase | Rattus norvegicus | Inhibition | = | 64 | % | 18808096 |
NPT4281 | Cell Line | MC9 | Mus musculus | Inhibition | = | 50 | % | 19178292 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 50 | % | 19178292 |
NPT324 | Individual Protein | Cyclooxygenase-1 | Ovis aries | Inhibition | = | 72 | % | 18473477 |
NPT31 | Individual Protein | Cyclooxygenase-2 | Homo sapiens | Inhibition | = | 86 | % | 18473477 |
NPT324 | Individual Protein | Cyclooxygenase-1 | Ovis aries | Inhibition | = | 57.96 | % | 10579873 |
NPT30 | Individual Protein | Cyclooxygenase-1 | Homo sapiens | IC50 | = | 11000 | nM | 10075763 |
NPT32 | Organism | Mus musculus | Mus musculus | Activity | = | 59 | % | 16872141 |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 28 | % | 16872141 |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 21 | % | 16872141 |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 18 | % | 16872141 |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 45 | % | 16872141 |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 25 | % | 16872141 |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 36 | % | 16872141 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 9.4 | % | 19398345 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 16.3 | % | 19398345 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 28.1 | % | 19398345 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 46.9 | % | 19398345 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 37.5 | % | 19398345 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 18.8 | % | 19398345 |
NPT2 | Others | Unspecified | Ki | = | 5.7 | nM | 20036557 | |
NPT605 | Organism | Homo sapiens | Homo sapiens | Activity | = | 0.99 | % | 20022146 |
NPT2 | Others | Unspecified | IC50 | = | 24000 | nM | 20888243 | |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Activity | = | 51 | % | 20888243 |
NPT312 | Organism | Saccharomyces cerevisiae | Saccharomyces cerevisiae | Potency | = | 18356.4 | nM | PubChem BioAssay data set |
NPT210 | Individual Protein | Thyroid stimulating hormone receptor | Homo sapiens | Potency | = | 794.3 | nM | PubChem BioAssay data set |
NPT324 | Individual Protein | Cyclooxygenase-1 | Ovis aries | IC50 | = | 180 | nM | 21280601 |
NPT31 | Individual Protein | Cyclooxygenase-2 | Homo sapiens | IC50 | = | 12400 | nM | 21280601 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ID50 | = | 29.7 | umol/kg | 21280601 |
NPT62 | Individual Protein | 6-phospho-1-fructokinase | Trypanosoma brucei | Potency | 756.9 | nM | PubChem BioAssay data set | |
NPT135 | Individual Protein | Chromobox protein homolog 1 | Homo sapiens | Potency | 6 | nM | PubChem BioAssay data set | |
NPT208 | Individual Protein | Cytochrome P450 1A2 | Homo sapiens | AC50 | = | 10000 | nM | PubChem BioAssay data set |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 23.9 | % | 21420857 |
NPT604 | Individual Protein | Serum albumin | Homo sapiens | Activity | = | 24.7 | % | 20869876 |
NPT604 | Individual Protein | Serum albumin | Homo sapiens | Activity | = | 91.3 | % | 20869876 |
NPT604 | Individual Protein | Serum albumin | Homo sapiens | Activity | = | 38.8 | % | 20869876 |
NPT604 | Individual Protein | Serum albumin | Homo sapiens | Activity | = | 79.9 | % | 20869876 |
NPT2 | Others | Unspecified | Ki | = | 5.7 | nM | 21802289 | |
NPT697 | Individual Protein | UDP-glucuronosyltransferase 2B7 | Homo sapiens | Activity | = | 1.8 | pm/min/mg | 10836148 |
NPT901 | Individual Protein | UDP-glucuronosyltransferase 1-1 | Homo sapiens | Activity | = | 0 | pm/min/mg | 10836148 |
NPT694 | Individual Protein | UDP-glucuronosyltransferase 1-3 | Homo sapiens | Activity | = | 39 | pm/min/mg | 10836148 |
NPT902 | Individual Protein | UDP-glucuronosyltransferase 1A4 | Homo sapiens | Activity | = | 0 | pm/min/mg | 10836148 |
NPT695 | Individual Protein | UDP-glucuronosyltransferase 1-8 | Homo sapiens | Activity | = | 0 | pm/min/mg | 10836148 |
NPT703 | Individual Protein | UDP-glucuronosyltransferase 1-9 | Homo sapiens | Activity | = | 40 | pm/min/mg | 10836148 |
NPT700 | Individual Protein | UDP-glucuronosyltransferase 2B10 | Homo sapiens | Activity | = | 0 | pm/min/mg | 10836148 |
NPT701 | Individual Protein | UDP-glucuronosyltransferase 2B4 | Homo sapiens | Activity | = | 0 | pm/min/mg | 10836148 |
NPT2 | Others | Unspecified | Ki | = | 172000 | nM | 15781124 | |
NPT2 | Others | Unspecified | Ki | = | 1100000 | nM | 15781124 | |
NPT30 | Individual Protein | Cyclooxygenase-1 | Homo sapiens | IC50 | = | 211 | nM | DrugMatrix in vitro pharmacology data |
NPT31 | Individual Protein | Cyclooxygenase-2 | Homo sapiens | IC50 | = | 17001 | nM | DrugMatrix in vitro pharmacology data |
NPT324 | Individual Protein | Cyclooxygenase-1 | Ovis aries | IC50 | = | 19500 | nM | 22119153 |
NPT31 | Individual Protein | Cyclooxygenase-2 | Homo sapiens | Inhibition | = | 68 | % | 22119153 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 71.7 | % | 22222039 |
NPT433 | Subcellular | Liver microsomes | Homo sapiens | Activity | = | 0.028 | nmol | 22931300 |
NPT305 | Individual Protein | Solute carrier organic anion transporter family member 1A4 | Rattus norvegicus | Activity | = | 52.2 | % | 11883641 |
NPT752 | Individual Protein | Solute carrier organic anion transporter family member 1A1 | Rattus norvegicus | Activity | = | 19.9 | % | 11883641 |
NPT665 | Individual Protein | Solute carrier family 22 member 6 | Homo sapiens | IC50 | = | 5800 | nM | 10991954 |
NPT666 | Individual Protein | Solute carrier family 22 member 6 | Rattus norvegicus | Ki | = | 2000 | nM | 10220563 |
NPT3507 | Individual Protein | Aldo-keto reductase family 1 member C2 | Homo sapiens | IC50 | = | 31300 | nM | 22877157 |
NPT3504 | Individual Protein | Aldo-keto-reductase family 1 member C3 | Homo sapiens | IC50 | = | 1100 | nM | 22877157 |
NPT3506 | Individual Protein | Aldo-keto reductase family 1 member C4 | Homo sapiens | IC50 | > | 100000 | nM | 22877157 |
NPT3505 | Individual Protein | Aldo-keto reductase family 1 member C1 | Homo sapiens | IC50 | > | 100000 | nM | 22877157 |
NPT32 | Organism | Mus musculus | Mus musculus | Activity | = | 67 | % | 23098566 |
NPT32 | Organism | Mus musculus | Mus musculus | Activity | = | 60 | % | 23098566 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Activity | = | 47 | % | 23098566 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Activity | = | 7.83 | nmol | 23059546 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 81.23 | % | 23059546 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 78.84 | % | 23059546 |
NPT31 | Individual Protein | Cyclooxygenase-2 | Homo sapiens | Inhibition | = | 88 | % | 10.1007/s00044-011-9726-x |
NPT324 | Individual Protein | Cyclooxygenase-1 | Ovis aries | Inhibition | = | 52 | % | 10.1007/s00044-011-9726-x |
NPT89 | Individual Protein | Seed lipoxygenase-1 | Glycine max | IC50 | = | 220000 | nM | 10.1007/s00044-011-9726-x |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 51 | % | 10.1007/s00044-011-9726-x |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 58 | % | 10.1007/s00044-010-9364-8 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 42 | % | 10.1007/s00044-010-9364-8 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 32 | % | 10.1007/s00044-010-9364-8 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 10 | % | 10.1007/s00044-010-9364-8 |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 61.36 | % | 10.1007/s00044-010-9364-8 |
NPT324 | Individual Protein | Cyclooxygenase-1 | Ovis aries | IC50 | = | 49000 | nM | 23219856 |
NPT324 | Individual Protein | Cyclooxygenase-1 | Ovis aries | Inhibition | = | 46 | % | 23219856 |
NPT2 | Others | Unspecified | Ratio IC50 | = | 0.01 | 23200247 | ||
NPT31 | Individual Protein | Cyclooxygenase-2 | Homo sapiens | IC50 | = | 12400 | nM | 23200247 |
NPT324 | Individual Protein | Cyclooxygenase-1 | Ovis aries | IC50 | = | 180 | nM | 23200247 |
NPT31 | Individual Protein | Cyclooxygenase-2 | Homo sapiens | Inhibition | = | 65 | % | 23219856 |
NPT32 | Organism | Mus musculus | Mus musculus | Activity | = | 51 | % | 23581491 |
NPT938 | Organism | Cavia porcellus | Cavia porcellus | Inhibition | = | 60 | % | 23260349 |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 30.63 | % | 23719287 |
NPT32 | Organism | Mus musculus | Mus musculus | ED50 | = | 21.76 | umol/kg | 23953687 |
NPT73 | Individual Protein | Solute carrier organic anion transporter family member 1B1 | Homo sapiens | Inhibition | = | 114.77 | % | 23571415 |
NPT72 | Individual Protein | Solute carrier organic anion transporter family member 1B3 | Homo sapiens | Inhibition | = | 103.46 | % | 23571415 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Activity | = | 0.25 | ml | 24273639 |
NPT2 | Others | Unspecified | IC50 | = | 2450000 | nM | 24273639 | |
NPT83 | Cell Line | MCF7 | Homo sapiens | IC50 | = | 2385000 | nM | 24273639 |
NPT15 | Cell Line | Jurkat | Homo sapiens | IC50 | = | 2550000 | nM | 24273639 |
NPT139 | Cell Line | HT-29 | Homo sapiens | IC50 | = | 2600000 | nM | 24273639 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Activity | = | 15 | pg/mg | 24273639 |
NPT2 | Others | Unspecified | Potency | 54941 | nM | PubChem BioAssay data set | ||
NPT104 | Individual Protein | Cerebroside-sulfatase | Homo sapiens | Potency | 8492.1 | nM | PubChem BioAssay data set | |
NPT153 | Individual Protein | Androgen Receptor | Homo sapiens | Potency | 43641.2 | nM | PubChem BioAssay data set | |
NPT49 | Individual Protein | DNA-(apurinic or apyrimidinic site) lyase | Homo sapiens | Potency | 5 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | 15355.3 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 7943.3 | nM | PubChem BioAssay data set | ||
NPT32 | Organism | Mus musculus | Mus musculus | Activity | = | 84.1 | % | 24569111 |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 36.65 | % | 24569111 |
NPT1665 | Individual Protein | Cyclooxygenase-1 | Bos taurus | Inhibition | = | 30 | % | 24568631 |
NPT31 | Individual Protein | Cyclooxygenase-2 | Homo sapiens | Inhibition | = | 55 | % | 24568631 |
NPT2 | Others | Unspecified | IC50 | = | 24000 | nM | 24568631 | |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 51 | % | 24568631 |
NPT419 | Organism | Oryctolagus cuniculus | Oryctolagus cuniculus | Inhibition | = | 55 | % | 140243 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 65 | % | 660585 |
NPT1016 | Organism | Canis familiaris | Canis lupus familiaris | ED50 | = | 13 | mg/kg | 309946 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | FC | = | 0.14 | 309946 | |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 2.1 | mg/kg | 950647 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | ED50 | = | 28 | mg/kg | 950647 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Ratio ED50 | = | 13 | 950647 | |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 46 | % | 722734 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 30 | % | 722734 |
NPT472 | Individual Protein | Vanilloid receptor | Homo sapiens | Activity | = | 109 | % | 25467164 |
NPT472 | Individual Protein | Vanilloid receptor | Homo sapiens | Activity | = | 107 | % | 25467164 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Activity | = | 580 | mm2 | 25466180 |
NPT32 | Organism | Mus musculus | Mus musculus | Activity | = | 49.2 | % | 25868745 |
NPT32 | Organism | Mus musculus | Mus musculus | Activity | = | 53.3 | % | 25868745 |
NPT2 | Others | Unspecified | EC50 | = | 756000 | nM | 25863493 | |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 36 | % | 25863493 |
NPT1463 | Individual Protein | Cytochrome P450 2J2 | Homo sapiens | IC50 | > | 50000 | nM | 23033255 |
NPT71 | Cell Line | HEK293 | Homo sapiens | Activity | < | 5.4 | % | 20926620 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 11 | % | 26494261 |
NPT1476 | Protein Family | Cyclooxygenase | Homo sapiens | Inhibition | > | 70 | % | 26810835 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 11 | % | 26750253 |
NPT32 | Organism | Mus musculus | Mus musculus | Activity | = | 46 | % | 10.1039/C5MD00308C |
NPT139 | Cell Line | HT-29 | Homo sapiens | IC50 | > | 50000 | nM | 26750401 |
NPT82 | Cell Line | MDA-MB-231 | Homo sapiens | IC50 | > | 50000 | nM | 26750401 |
NPT2 | Others | Unspecified | IC50 | > | 50000 | nM | 26750401 | |
NPT2644 | Cell Line | UACC-903 | Homo sapiens | IC50 | > | 50000 | nM | 26750401 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC111088 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
0.9076 | High Similarity | NPC328694 |
0.8974 | High Similarity | NPC109241 |
0.8769 | High Similarity | NPC213122 |
0.8632 | High Similarity | NPC234639 |
0.8618 | High Similarity | NPC478121 |
0.8605 | High Similarity | NPC470725 |
0.8571 | High Similarity | NPC75432 |
0.856 | High Similarity | NPC121168 |
0.8473 | Intermediate Similarity | NPC183103 |
0.8468 | Intermediate Similarity | NPC103916 |
0.8438 | Intermediate Similarity | NPC474737 |
0.84 | Intermediate Similarity | NPC241001 |
0.8376 | Intermediate Similarity | NPC1065 |
0.8372 | Intermediate Similarity | NPC428300 |
0.837 | Intermediate Similarity | NPC475104 |
0.8361 | Intermediate Similarity | NPC322358 |
0.8346 | Intermediate Similarity | NPC274876 |
0.8346 | Intermediate Similarity | NPC27394 |
0.8333 | Intermediate Similarity | NPC312560 |
0.8321 | Intermediate Similarity | NPC475102 |
0.8306 | Intermediate Similarity | NPC63010 |
0.8306 | Intermediate Similarity | NPC205502 |
0.8295 | Intermediate Similarity | NPC177925 |
0.8273 | Intermediate Similarity | NPC471305 |
0.8273 | Intermediate Similarity | NPC260152 |
0.8258 | Intermediate Similarity | NPC258073 |
0.8254 | Intermediate Similarity | NPC129176 |
0.8248 | Intermediate Similarity | NPC29599 |
0.8244 | Intermediate Similarity | NPC206028 |
0.824 | Intermediate Similarity | NPC42657 |
0.8226 | Intermediate Similarity | NPC25648 |
0.8222 | Intermediate Similarity | NPC471670 |
0.8211 | Intermediate Similarity | NPC51345 |
0.8205 | Intermediate Similarity | NPC241224 |
0.8189 | Intermediate Similarity | NPC162935 |
0.8189 | Intermediate Similarity | NPC249340 |
0.8182 | Intermediate Similarity | NPC249425 |
0.8175 | Intermediate Similarity | NPC470407 |
0.8162 | Intermediate Similarity | NPC470722 |
0.8162 | Intermediate Similarity | NPC470721 |
0.8162 | Intermediate Similarity | NPC6100 |
0.8162 | Intermediate Similarity | NPC156888 |
0.8156 | Intermediate Similarity | NPC163846 |
0.8156 | Intermediate Similarity | NPC225173 |
0.8125 | Intermediate Similarity | NPC152946 |
0.8125 | Intermediate Similarity | NPC176208 |
0.812 | Intermediate Similarity | NPC239134 |
0.812 | Intermediate Similarity | NPC164295 |
0.8116 | Intermediate Similarity | NPC168471 |
0.8112 | Intermediate Similarity | NPC261322 |
0.811 | Intermediate Similarity | NPC277798 |
0.811 | Intermediate Similarity | NPC100108 |
0.8099 | Intermediate Similarity | NPC125801 |
0.8092 | Intermediate Similarity | NPC223807 |
0.8088 | Intermediate Similarity | NPC475549 |
0.8083 | Intermediate Similarity | NPC75440 |
0.808 | Intermediate Similarity | NPC240664 |
0.8074 | Intermediate Similarity | NPC68779 |
0.8074 | Intermediate Similarity | NPC176814 |
0.8074 | Intermediate Similarity | NPC4982 |
0.8074 | Intermediate Similarity | NPC300776 |
0.8074 | Intermediate Similarity | NPC5310 |
0.8071 | Intermediate Similarity | NPC158871 |
0.8065 | Intermediate Similarity | NPC283169 |
0.8051 | Intermediate Similarity | NPC38209 |
0.8049 | Intermediate Similarity | NPC35344 |
0.8049 | Intermediate Similarity | NPC141003 |
0.8047 | Intermediate Similarity | NPC177291 |
0.8047 | Intermediate Similarity | NPC194416 |
0.8045 | Intermediate Similarity | NPC27659 |
0.8045 | Intermediate Similarity | NPC245395 |
0.8034 | Intermediate Similarity | NPC300166 |
0.8033 | Intermediate Similarity | NPC470723 |
0.8029 | Intermediate Similarity | NPC186647 |
0.8015 | Intermediate Similarity | NPC113295 |
0.8015 | Intermediate Similarity | NPC22644 |
0.8014 | Intermediate Similarity | NPC290038 |
0.8014 | Intermediate Similarity | NPC91694 |
0.8014 | Intermediate Similarity | NPC300603 |
0.8 | Intermediate Similarity | NPC94076 |
0.8 | Intermediate Similarity | NPC312105 |
0.8 | Intermediate Similarity | NPC470406 |
0.8 | Intermediate Similarity | NPC19290 |
0.8 | Intermediate Similarity | NPC182255 |
0.8 | Intermediate Similarity | NPC89630 |
0.8 | Intermediate Similarity | NPC201297 |
0.7986 | Intermediate Similarity | NPC165172 |
0.7985 | Intermediate Similarity | NPC279596 |
0.7984 | Intermediate Similarity | NPC221275 |
0.7984 | Intermediate Similarity | NPC30462 |
0.7971 | Intermediate Similarity | NPC265335 |
0.7971 | Intermediate Similarity | NPC233707 |
0.797 | Intermediate Similarity | NPC131684 |
0.797 | Intermediate Similarity | NPC57552 |
0.7969 | Intermediate Similarity | NPC32322 |
0.7969 | Intermediate Similarity | NPC259703 |
0.7966 | Intermediate Similarity | NPC298224 |
0.7956 | Intermediate Similarity | NPC115861 |
0.7955 | Intermediate Similarity | NPC53781 |
0.7945 | Intermediate Similarity | NPC44606 |
0.7943 | Intermediate Similarity | NPC84266 |
0.7941 | Intermediate Similarity | NPC324117 |
0.7941 | Intermediate Similarity | NPC209858 |
0.7939 | Intermediate Similarity | NPC4286 |
0.7939 | Intermediate Similarity | NPC257589 |
0.7939 | Intermediate Similarity | NPC105031 |
0.7939 | Intermediate Similarity | NPC232387 |
0.7939 | Intermediate Similarity | NPC76119 |
0.7939 | Intermediate Similarity | NPC53305 |
0.7934 | Intermediate Similarity | NPC201959 |
0.7931 | Intermediate Similarity | NPC119929 |
0.7923 | Intermediate Similarity | NPC275145 |
0.7923 | Intermediate Similarity | NPC473942 |
0.7914 | Intermediate Similarity | NPC1268 |
0.791 | Intermediate Similarity | NPC253488 |
0.7902 | Intermediate Similarity | NPC211565 |
0.7902 | Intermediate Similarity | NPC39361 |
0.7902 | Intermediate Similarity | NPC60389 |
0.7902 | Intermediate Similarity | NPC58752 |
0.7899 | Intermediate Similarity | NPC474603 |
0.7899 | Intermediate Similarity | NPC290601 |
0.7899 | Intermediate Similarity | NPC12987 |
0.7895 | Intermediate Similarity | NPC23012 |
0.7895 | Intermediate Similarity | NPC215300 |
0.7895 | Intermediate Similarity | NPC96024 |
0.7895 | Intermediate Similarity | NPC81261 |
0.7895 | Intermediate Similarity | NPC38017 |
0.7891 | Intermediate Similarity | NPC477691 |
0.7883 | Intermediate Similarity | NPC89504 |
0.7883 | Intermediate Similarity | NPC95485 |
0.7883 | Intermediate Similarity | NPC252343 |
0.7883 | Intermediate Similarity | NPC88065 |
0.7883 | Intermediate Similarity | NPC152209 |
0.7883 | Intermediate Similarity | NPC470844 |
0.7879 | Intermediate Similarity | NPC474264 |
0.7879 | Intermediate Similarity | NPC92207 |
0.7879 | Intermediate Similarity | NPC127937 |
0.7872 | Intermediate Similarity | NPC69755 |
0.7872 | Intermediate Similarity | NPC229218 |
0.7872 | Intermediate Similarity | NPC176030 |
0.7872 | Intermediate Similarity | NPC141817 |
0.7872 | Intermediate Similarity | NPC192597 |
0.7872 | Intermediate Similarity | NPC169214 |
0.7872 | Intermediate Similarity | NPC250755 |
0.7869 | Intermediate Similarity | NPC58865 |
0.7869 | Intermediate Similarity | NPC259554 |
0.7868 | Intermediate Similarity | NPC472524 |
0.7868 | Intermediate Similarity | NPC59459 |
0.7868 | Intermediate Similarity | NPC49742 |
0.7863 | Intermediate Similarity | NPC138248 |
0.7863 | Intermediate Similarity | NPC470162 |
0.7863 | Intermediate Similarity | NPC228503 |
0.7863 | Intermediate Similarity | NPC470163 |
0.7863 | Intermediate Similarity | NPC236189 |
0.7862 | Intermediate Similarity | NPC329933 |
0.7862 | Intermediate Similarity | NPC291049 |
0.7862 | Intermediate Similarity | NPC233267 |
0.7857 | Intermediate Similarity | NPC82336 |
0.7857 | Intermediate Similarity | NPC472523 |
0.7857 | Intermediate Similarity | NPC78987 |
0.7852 | Intermediate Similarity | NPC191395 |
0.7847 | Intermediate Similarity | NPC470757 |
0.7847 | Intermediate Similarity | NPC478163 |
0.7847 | Intermediate Similarity | NPC142863 |
0.7846 | Intermediate Similarity | NPC46634 |
0.7846 | Intermediate Similarity | NPC164947 |
0.7846 | Intermediate Similarity | NPC11250 |
0.7836 | Intermediate Similarity | NPC276238 |
0.7836 | Intermediate Similarity | NPC241354 |
0.7829 | Intermediate Similarity | NPC131868 |
0.7829 | Intermediate Similarity | NPC164852 |
0.7826 | Intermediate Similarity | NPC90431 |
0.7826 | Intermediate Similarity | NPC141934 |
0.7823 | Intermediate Similarity | NPC199462 |
0.7823 | Intermediate Similarity | NPC280760 |
0.7823 | Intermediate Similarity | NPC477690 |
0.7823 | Intermediate Similarity | NPC175978 |
0.782 | Intermediate Similarity | NPC470841 |
0.782 | Intermediate Similarity | NPC281020 |
0.7817 | Intermediate Similarity | NPC53016 |
0.7817 | Intermediate Similarity | NPC66593 |
0.7817 | Intermediate Similarity | NPC472840 |
0.7812 | Intermediate Similarity | NPC61779 |
0.7812 | Intermediate Similarity | NPC234956 |
0.7812 | Intermediate Similarity | NPC299406 |
0.7812 | Intermediate Similarity | NPC264976 |
0.7812 | Intermediate Similarity | NPC472593 |
0.781 | Intermediate Similarity | NPC1249 |
0.7803 | Intermediate Similarity | NPC280767 |
0.7803 | Intermediate Similarity | NPC29008 |
0.7803 | Intermediate Similarity | NPC278955 |
0.7803 | Intermediate Similarity | NPC228771 |
0.7803 | Intermediate Similarity | NPC137750 |
0.7803 | Intermediate Similarity | NPC137416 |
0.7803 | Intermediate Similarity | NPC9067 |
0.7803 | Intermediate Similarity | NPC266705 |
0.7803 | Intermediate Similarity | NPC105718 |
0.7801 | Intermediate Similarity | NPC124365 |
0.7795 | Intermediate Similarity | NPC195466 |
0.7795 | Intermediate Similarity | NPC45794 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC111088 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
1.0 | High Similarity | NPD1283 | Approved |
0.9744 | High Similarity | NPD1281 | Approved |
0.916 | High Similarity | NPD1651 | Approved |
0.8906 | High Similarity | NPD2979 | Phase 3 |
0.8571 | High Similarity | NPD2438 | Suspended |
0.8571 | High Similarity | NPD2531 | Phase 2 |
0.856 | High Similarity | NPD1608 | Approved |
0.8468 | Intermediate Similarity | NPD4626 | Approved |
0.8456 | Intermediate Similarity | NPD7003 | Approved |
0.832 | Intermediate Similarity | NPD17 | Approved |
0.824 | Intermediate Similarity | NPD5691 | Approved |
0.8189 | Intermediate Similarity | NPD1611 | Approved |
0.8162 | Intermediate Similarity | NPD4476 | Approved |
0.8162 | Intermediate Similarity | NPD4477 | Approved |
0.812 | Intermediate Similarity | NPD8032 | Phase 2 |
0.8102 | Intermediate Similarity | NPD2346 | Discontinued |
0.806 | Intermediate Similarity | NPD4060 | Phase 1 |
0.8029 | Intermediate Similarity | NPD2935 | Discontinued |
0.8028 | Intermediate Similarity | NPD6273 | Approved |
0.8016 | Intermediate Similarity | NPD1894 | Discontinued |
0.8 | Intermediate Similarity | NPD1876 | Approved |
0.7969 | Intermediate Similarity | NPD3847 | Discontinued |
0.7956 | Intermediate Similarity | NPD2799 | Discontinued |
0.7926 | Intermediate Similarity | NPD4140 | Approved |
0.7923 | Intermediate Similarity | NPD3600 | Clinical (unspecified phase) |
0.7868 | Intermediate Similarity | NPD6355 | Discontinued |
0.7862 | Intermediate Similarity | NPD5808 | Clinical (unspecified phase) |
0.7846 | Intermediate Similarity | NPD1481 | Phase 2 |
0.7846 | Intermediate Similarity | NPD3972 | Approved |
0.7812 | Intermediate Similarity | NPD5585 | Approved |
0.781 | Intermediate Similarity | NPD4579 | Clinical (unspecified phase) |
0.7803 | Intermediate Similarity | NPD2797 | Approved |
0.7786 | Intermediate Similarity | NPD1669 | Approved |
0.7769 | Intermediate Similarity | NPD1535 | Discovery |
0.7752 | Intermediate Similarity | NPD3019 | Approved |
0.7752 | Intermediate Similarity | NPD1778 | Approved |
0.7752 | Intermediate Similarity | NPD2932 | Approved |
0.7721 | Intermediate Similarity | NPD6663 | Approved |
0.7714 | Intermediate Similarity | NPD2343 | Clinical (unspecified phase) |
0.7704 | Intermediate Similarity | NPD7095 | Approved |
0.7687 | Intermediate Similarity | NPD5736 | Approved |
0.7676 | Intermediate Similarity | NPD4109 | Clinical (unspecified phase) |
0.7676 | Intermediate Similarity | NPD4628 | Phase 3 |
0.7676 | Intermediate Similarity | NPD4110 | Phase 3 |
0.766 | Intermediate Similarity | NPD970 | Clinical (unspecified phase) |
0.7647 | Intermediate Similarity | NPD6798 | Discontinued |
0.7638 | Intermediate Similarity | NPD709 | Approved |
0.763 | Intermediate Similarity | NPD2614 | Approved |
0.7619 | Intermediate Similarity | NPD3226 | Approved |
0.7619 | Intermediate Similarity | NPD1241 | Discontinued |
0.7619 | Intermediate Similarity | NPD7458 | Discontinued |
0.7619 | Intermediate Similarity | NPD5283 | Phase 1 |
0.7612 | Intermediate Similarity | NPD2798 | Approved |
0.7612 | Intermediate Similarity | NPD4624 | Approved |
0.7603 | Intermediate Similarity | NPD7427 | Discontinued |
0.7586 | Intermediate Similarity | NPD7004 | Clinical (unspecified phase) |
0.754 | Intermediate Similarity | NPD5535 | Approved |
0.7533 | Intermediate Similarity | NPD7819 | Suspended |
0.7532 | Intermediate Similarity | NPD6232 | Discontinued |
0.7521 | Intermediate Similarity | NPD688 | Clinical (unspecified phase) |
0.7519 | Intermediate Similarity | NPD4359 | Approved |
0.7518 | Intermediate Similarity | NPD2313 | Discontinued |
0.7518 | Intermediate Similarity | NPD6859 | Clinical (unspecified phase) |
0.7518 | Intermediate Similarity | NPD3764 | Approved |
0.7518 | Intermediate Similarity | NPD3268 | Approved |
0.75 | Intermediate Similarity | NPD7473 | Discontinued |
0.7483 | Intermediate Similarity | NPD7421 | Clinical (unspecified phase) |
0.7467 | Intermediate Similarity | NPD37 | Approved |
0.7464 | Intermediate Similarity | NPD4062 | Phase 3 |
0.7464 | Intermediate Similarity | NPD6233 | Phase 2 |
0.7447 | Intermediate Similarity | NPD4308 | Phase 3 |
0.7445 | Intermediate Similarity | NPD4625 | Phase 3 |
0.7431 | Intermediate Similarity | NPD3750 | Approved |
0.7429 | Intermediate Similarity | NPD4097 | Suspended |
0.7429 | Intermediate Similarity | NPD1607 | Approved |
0.7424 | Intermediate Similarity | NPD3023 | Approved |
0.7424 | Intermediate Similarity | NPD3026 | Approved |
0.7413 | Intermediate Similarity | NPD4534 | Discontinued |
0.7413 | Intermediate Similarity | NPD5958 | Discontinued |
0.7407 | Intermediate Similarity | NPD3267 | Approved |
0.7407 | Intermediate Similarity | NPD1164 | Approved |
0.7407 | Intermediate Similarity | NPD3266 | Approved |
0.7405 | Intermediate Similarity | NPD3024 | Approved |
0.7405 | Intermediate Similarity | NPD3025 | Approved |
0.7402 | Intermediate Similarity | NPD7635 | Approved |
0.7397 | Intermediate Similarity | NPD6143 | Clinical (unspecified phase) |
0.7394 | Intermediate Similarity | NPD5404 | Approved |
0.7394 | Intermediate Similarity | NPD5406 | Approved |
0.7394 | Intermediate Similarity | NPD5405 | Approved |
0.7394 | Intermediate Similarity | NPD5408 | Approved |
0.7391 | Intermediate Similarity | NPD1699 | Clinical (unspecified phase) |
0.7388 | Intermediate Similarity | NPD5327 | Phase 3 |
0.7368 | Intermediate Similarity | NPD1201 | Approved |
0.7347 | Intermediate Similarity | NPD2534 | Approved |
0.7347 | Intermediate Similarity | NPD2532 | Approved |
0.7347 | Intermediate Similarity | NPD2533 | Approved |
0.7343 | Intermediate Similarity | NPD5762 | Approved |
0.7343 | Intermediate Similarity | NPD5763 | Approved |
0.7339 | Intermediate Similarity | NPD3134 | Approved |
0.7333 | Intermediate Similarity | NPD196 | Phase 1 |
0.7328 | Intermediate Similarity | NPD9545 | Approved |
0.7324 | Intermediate Similarity | NPD3748 | Approved |
0.7324 | Intermediate Similarity | NPD4108 | Discontinued |
0.7323 | Intermediate Similarity | NPD228 | Approved |
0.732 | Intermediate Similarity | NPD4967 | Phase 2 |
0.732 | Intermediate Similarity | NPD4966 | Approved |
0.732 | Intermediate Similarity | NPD4965 | Approved |
0.7319 | Intermediate Similarity | NPD7008 | Discontinued |
0.7315 | Intermediate Similarity | NPD2370 | Clinical (unspecified phase) |
0.731 | Intermediate Similarity | NPD6398 | Clinical (unspecified phase) |
0.731 | Intermediate Similarity | NPD8166 | Discontinued |
0.7308 | Intermediate Similarity | NPD7229 | Phase 3 |
0.7308 | Intermediate Similarity | NPD6747 | Phase 1 |
0.7299 | Intermediate Similarity | NPD454 | Approved |
0.7296 | Intermediate Similarity | NPD5844 | Phase 1 |
0.7292 | Intermediate Similarity | NPD2897 | Discontinued |
0.7287 | Intermediate Similarity | NPD5951 | Approved |
0.7286 | Intermediate Similarity | NPD1240 | Approved |
0.7286 | Intermediate Similarity | NPD4307 | Phase 2 |
0.728 | Intermediate Similarity | NPD2342 | Discontinued |
0.7279 | Intermediate Similarity | NPD987 | Approved |
0.7279 | Intermediate Similarity | NPD1203 | Approved |
0.7273 | Intermediate Similarity | NPD6099 | Approved |
0.7273 | Intermediate Similarity | NPD1501 | Clinical (unspecified phase) |
0.7273 | Intermediate Similarity | NPD6100 | Approved |
0.7273 | Intermediate Similarity | NPD3020 | Approved |
0.7266 | Intermediate Similarity | NPD6812 | Clinical (unspecified phase) |
0.7266 | Intermediate Similarity | NPD411 | Approved |
0.7265 | Intermediate Similarity | NPD1239 | Approved |
0.7259 | Intermediate Similarity | NPD4379 | Clinical (unspecified phase) |
0.7252 | Intermediate Similarity | NPD7644 | Approved |
0.7252 | Intermediate Similarity | NPD5536 | Phase 2 |
0.725 | Intermediate Similarity | NPD1566 | Phase 3 |
0.725 | Intermediate Similarity | NPD1564 | Approved |
0.725 | Intermediate Similarity | NPD1565 | Approved |
0.7234 | Intermediate Similarity | NPD4622 | Approved |
0.7234 | Intermediate Similarity | NPD5735 | Approved |
0.7234 | Intermediate Similarity | NPD4618 | Approved |
0.7226 | Intermediate Similarity | NPD6234 | Discontinued |
0.7222 | Intermediate Similarity | NPD6800 | Clinical (unspecified phase) |
0.7222 | Intermediate Similarity | NPD2344 | Approved |
0.7219 | Intermediate Similarity | NPD7028 | Phase 2 |
0.7218 | Intermediate Similarity | NPD2667 | Approved |
0.7218 | Intermediate Similarity | NPD2668 | Approved |
0.7214 | Intermediate Similarity | NPD4870 | Approved |
0.7194 | Intermediate Similarity | NPD5952 | Clinical (unspecified phase) |
0.7185 | Intermediate Similarity | NPD2230 | Approved |
0.7185 | Intermediate Similarity | NPD2232 | Approved |
0.7185 | Intermediate Similarity | NPD9717 | Approved |
0.7185 | Intermediate Similarity | NPD2233 | Approved |
0.7183 | Intermediate Similarity | NPD6353 | Approved |
0.7176 | Intermediate Similarity | NPD9493 | Approved |
0.7174 | Intermediate Similarity | NPD9494 | Approved |
0.7171 | Intermediate Similarity | NPD6873 | Phase 2 |
0.7165 | Intermediate Similarity | NPD5451 | Approved |
0.7163 | Intermediate Similarity | NPD3620 | Phase 2 |
0.7163 | Intermediate Similarity | NPD3619 | Clinical (unspecified phase) |
0.7153 | Intermediate Similarity | NPD1551 | Phase 2 |
0.7153 | Intermediate Similarity | NPD1470 | Approved |
0.7143 | Intermediate Similarity | NPD1358 | Approved |
0.7143 | Intermediate Similarity | NPD7985 | Registered |
0.7133 | Intermediate Similarity | NPD7097 | Phase 1 |
0.7133 | Intermediate Similarity | NPD5688 | Approved |
0.7133 | Intermediate Similarity | NPD5689 | Approved |
0.7133 | Intermediate Similarity | NPD1914 | Approved |
0.7125 | Intermediate Similarity | NPD7177 | Discontinued |
0.7123 | Intermediate Similarity | NPD5698 | Clinical (unspecified phase) |
0.7122 | Intermediate Similarity | NPD6832 | Phase 2 |
0.7113 | Intermediate Similarity | NPD1899 | Clinical (unspecified phase) |
0.7111 | Intermediate Similarity | NPD1610 | Phase 2 |
0.7111 | Intermediate Similarity | NPD1547 | Clinical (unspecified phase) |
0.7107 | Intermediate Similarity | NPD288 | Approved |
0.7103 | Intermediate Similarity | NPD6002 | Phase 3 |
0.7103 | Intermediate Similarity | NPD6005 | Phase 3 |
0.7103 | Intermediate Similarity | NPD1471 | Phase 3 |
0.7103 | Intermediate Similarity | NPD6003 | Clinical (unspecified phase) |
0.7103 | Intermediate Similarity | NPD6006 | Clinical (unspecified phase) |
0.7103 | Intermediate Similarity | NPD6004 | Phase 3 |
0.7101 | Intermediate Similarity | NPD6917 | Clinical (unspecified phase) |
0.7097 | Intermediate Similarity | NPD7768 | Phase 2 |
0.7097 | Intermediate Similarity | NPD1931 | Clinical (unspecified phase) |
0.7097 | Intermediate Similarity | NPD1930 | Approved |
0.7097 | Intermediate Similarity | NPD1929 | Approved |
0.7095 | Intermediate Similarity | NPD6666 | Approved |
0.7095 | Intermediate Similarity | NPD6667 | Approved |
0.709 | Intermediate Similarity | NPD2286 | Discontinued |
0.709 | Intermediate Similarity | NPD3412 | Clinical (unspecified phase) |
0.7087 | Intermediate Similarity | NPD2684 | Approved |
0.7083 | Intermediate Similarity | NPD1510 | Phase 2 |
0.7083 | Intermediate Similarity | NPD1509 | Clinical (unspecified phase) |
0.7078 | Intermediate Similarity | NPD8455 | Phase 2 |
0.7077 | Intermediate Similarity | NPD1398 | Phase 1 |
0.7071 | Intermediate Similarity | NPD5163 | Phase 2 |
0.7068 | Intermediate Similarity | NPD3091 | Approved |
0.7063 | Intermediate Similarity | NPD968 | Approved |
0.7063 | Intermediate Similarity | NPD6653 | Approved |
0.7059 | Intermediate Similarity | NPD1840 | Phase 2 |
0.7055 | Intermediate Similarity | NPD7596 | Clinical (unspecified phase) |
0.705 | Intermediate Similarity | NPD2861 | Phase 2 |
0.7045 | Intermediate Similarity | NPD7340 | Approved |
Molecular Weight:   | 230.09 |
ALogP:   | 0.0032 |
MLogP:   | 2.67 |
XLogP:   | 3.75 |
# Rotatable Bonds:   | 6 |
Polar Surface Area:   | 46.53 |
# H-Bond Aceptor:   | 2 |
# H-Bond Donor:   | 1 |
# Rings:   | 2 |
# Heavy Atoms:   | 17 |